Will Amgen’s BiTE antibody compete with or complement CAR-Ts in myeloma?

The data for AMG 420 are early, an Amgen executive said, but where to place the drug relative to CAR-Ts is a “million-dollar question.”

Article Source: Will Amgen’s BiTE antibody compete with or complement CAR-Ts in myeloma?.